We are live on
!
Find out more
Nicholas Company Portfolio holdings
AUM
$5.47B
Turnover
6.8%
1-Year Est. Return
16.96%
This Fund
S&P 500
This Quarter
Est. Return
+4.79%
1 Year Est. Return
+16.96%
3 Year Est. Return
+65.72%
5 Year Est. Return
+94.16%
10 Year Est. Return
+404.17%
AUM
$4.21B
AUM Growth
+$64.6M
(+1.6%)
Cap. Flow
-$99.3M
Cap. Flow
% of AUM
-2.36%
Top 10 Holdings %
Top 10 Hldgs %
30.14%
Holding
265
New
11
Increased
89
Reduced
79
Closed
19
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$36.1M |
| 2 |
ADT Corp
ADT
|
+$34.9M |
| 3 |
Pfizer
PFE
|
+$27.7M |
| 4 |
Chubb
CB
|
+$19.3M |
| 5 |
Johnson Controls International
JCI
|
+$15.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LO
LORILLARD INC COM STK
LO
|
+$79.3M |
| 2 |
MCRS
MICROS SYSTEMS INC
MCRS
|
+$73.6M |
| 3 |
Motorola Solutions
MSI
|
+$51M |
| 4 |
Bausch Health
BHC
|
+$23.5M |
| 5 |
DTV
DIRECTV COM STK (DE)
DTV
|
+$15.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28.03% |
| 2 | Consumer Discretionary | 15.41% |
| 3 | Industrials | 15.12% |
| 4 | Financials | 11.91% |
| 5 | Technology | 8.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ENLK
151
DELISTED
EnLink Midstream Partners, LP
ENLK
| $4.22M | 0.1% |
134,350
+1,000
| +0.7% | +$30.6K |
2013 Q4
2 quarters
|
|
152
National Presto Industries
NPK
$1.05B
| $4.22M | 0.1% |
57,950
| – | – |
2013 Q2
4 quarters
|
|
|
IBKC
153
DELISTED
IBERIABANK Corp
IBKC
| $4.21M | 0.1% |
60,820
-75
| -0.1% | -$4.91K |
2013 Q2
4 quarters
|
|
|
ROSE
154
DELISTED
ROSETTA RESOURCES INC
ROSE
| $4.21M | 0.1% |
76,710
+20
| +0% | +$972 |
2013 Q2
4 quarters
|
|
155
Zurn Elkay Water Solutions
ZWS
$7.75B
| $4.12M | 0.1% |
304,020
+114
| +0% | +$1.51K |
2013 Q4
2 quarters
|
|
156
Prestige Consumer Healthcare
PBH
$2.37B
| $4.1M | 0.1% |
121,125
+200
| +0.2% | +$6.41K |
2013 Q2
4 quarters
|
|
157
Globus Medical
GMED
$10.5B
| $4.1M | 0.1% |
171,550
-200
| -0.1% | -$4.82K |
2013 Q2
4 quarters
|
|
158
Helmerich & Payne
HP
$3.71B
| $4.07M | 0.1% |
35,030
-25,030
| -42% | -$2.74M |
2013 Q2
4 quarters
|
|
159
Acadia Healthcare
ACHC
$2.84B
| $4.02M | 0.1% |
88,365
+35,330
| +67% | +$1.55M |
2013 Q2
4 quarters
|
|
160
Dorman Products
DORM
$3.67B
| $3.98M | 0.09% |
80,760
-40
| -0% | -$2.18K |
2013 Q2
4 quarters
|
|
161
Community Bank
CBU
$3.17B
| $3.96M | 0.09% |
109,545
-630
| -0.6% | -$23.3K |
2013 Q2
4 quarters
|
|
162
Abbott
ABT
$181B
| $3.96M | 0.09% |
51,345
+50,045
| +3,850% | +$1.97M |
2013 Q2
4 quarters
|
|
|
EPAY
163
DELISTED
Bottomline Technologies Inc
EPAY
| $3.93M | 0.09% |
131,340
+5,000
| +4% | +$154K |
2013 Q2
4 quarters
|
|
164
Evertec
EVTC
$1.88B
| $3.92M | 0.09% |
161,600
-20
| -0% | -$477 |
2013 Q3
3 quarters
|
|
165
Church & Dwight Co
CHD
$24.5B
| $3.85M | 0.09% |
110,100
| – | – |
2013 Q4
2 quarters
|
|
|
XLNX
166
DELISTED
Xilinx Inc
XLNX
| $3.79M | 0.09% |
80,075
| – | – |
2013 Q2
4 quarters
|
|
167
Gentex
GNTX
$4.47B
| $3.79M | 0.09% |
+260,250
| New | +$3.8M |
2014 Q2
0 quarters
|
|
168
Aptiv
APTV
$9.52B
| $3.78M | 0.09% |
55,050
| – | – |
2014 Q1
1 quarter
|
|
|
CATM
169
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
| $3.78M | 0.09% |
110,945
+9,865
| +10% | +$330K |
2013 Q2
4 quarters
|
|
|
CAVM
170
DELISTED
Cavium, Inc.
CAVM
| $3.76M | 0.09% |
75,710
-20,435
| -21% | -$940K |
2013 Q2
4 quarters
|
|
171
First Financial Bancorp
FFBC
$3.33B
| $3.76M | 0.09% |
218,354
+6,750
| +3% | +$113K |
2013 Q2
4 quarters
|
|
172
Thor Industries
THO
$3.64B
| $3.73M | 0.09% |
65,660
+70
| +0.1% | +$4.2K |
2013 Q2
4 quarters
|
|
|
WWAV
173
DELISTED
The WhiteWave Foods Company
WWAV
| $3.73M | 0.09% |
115,110
-35,040
| -23% | -$1.05M |
2013 Q4
2 quarters
|
|
|
TNGO
174
DELISTED
Tangoe, Inc.
TNGO
| $3.73M | 0.09% |
247,380
+9,925
| +4% | +$154K |
2013 Q2
4 quarters
|
|
175
Huntington Bancshares
HBAN
$31.3B
| $3.72M | 0.09% |
390,385
+60,100
| +18% | +$565K |
2014 Q1
1 quarter
|
|
Similar funds
SCM
Nicholas Company's Q2 2014 Portfolio in Review
As of Q2 2014, Nicholas Company held 265 positions worth $4.21B, up 1.6% from $4.14B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Nicholas Company's Q2 2014 filing shows 11 new, 89 increased, 79 reduced and 19 closed positions. Its largest new stake was Celgene Corp: 474,120 shares worth $40.7M. The largest sale was LORILLARD INC COM STK, an estimated $79.3M.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Consumer Discretionary and Industrials.
- Nicholas Company's largest Q2 2014 buy was Celgene Corp: 474,120 shares worth $40.7M.
- Nicholas Company added most to Pfizer in Q2 2014, an estimated $27.7M increase.
- Nicholas Company's biggest Q2 2014 reduction was Bausch Health, cutting an estimated $23.5M.
- Nicholas Company fully exited LORILLARD INC COM STK in Q2 2014, selling an estimated $79.3M.
- Nicholas Company's ten largest holdings make up 30% of its $4.21B portfolio in Q2 2014.
- Nicholas Company opened 11 new positions and closed 19 in Q2 2014.
- Nicholas Company's portfolio value rose 1.6% quarter-over-quarter to $4.21B.
Based on Nicholas Company's 13F filing for Q2 2014, filed 14 Aug 2014.